Laboratory Services

HPV, Human Papillomavirus

Name: Incyte Diagnostics
Address: 13103 E Mansfield Ave, Spokane Valley, Washington, 99216, USA
Telephone: +1-If-you-have-questions-regarding-your-bill-or-would-like-to-make-a-payment,-please-visit-our-Billing-page-by-clicking-"Pay-Online"-at-the-top-of-the-page-For-other-inquiries,-please-call-us-at-509-892-2700

Updated Test Information:

Test Description	HPV, Human Papillomavirus
Synonym(s)	HR HPV, HPV
Test ID	ThinPrep: THPV - HPV Only - Liquid Based Pap Collection (NO PAP) TPAPV - Pap w/HPV (regardless of Pap result) TPAPVG - Pap w/HPV (regardless) and reflex 16/18 if HPV+ TPAPVGN - Pap w/HPV (regardless) and reflex 16/18 if Pap – and HPV+ TPAPA - Pap w/HPV if ASCUS TPAPACT - Pap w/HPV if ASCUS and CT TPAPAGC - Pap w/HPV if ASCUS and GC TPAPAGCCT - Pap w/HPV if ASCUS and GCCT ANALHCYT - Anal cytology with HPV ANALHCYTG - Anal cytology with HPV and reflex to 16/18
General Information	This assay detects RNA from 14 high-risk types of human papillomavirus (HPV) but it does not differentiate between them. A positive result indicates the presence of HPV RNA due to one or more of the following high-risk genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Specific genotyping for HPV types 16 and 18/45 may be requested on HPV positive samples.
Specimen Type	Cervical/endocervical collection, vaginal collection
Specimen Requirements	ThinPrep collection vial
Required Information	Complete the Incyte Diagnostics requisition with the patient's demographics and relevant clinical history. Label specimen container with the patient's full first and last name, second unique identifier, and specimen source/site.
Unacceptable Specimen Conditions	Improper or inadequate patient identification, improper fixative
Limitations	Excess blood/inflammation/lubricant, scant cellularity Detection of high-risk HPV mRNA is dependent on the number of copies present in the specimen and may be affected by specimen collection methods, patient factors, stage of infection and the presence of interfering substances. A negative Aptima HPV assay result does not exclude the possibility of cytologic abnormalities or of future or underlying CIN2, CIN3, or cancer. The Aptima HPV assay should be interpreted in conjunction with other laboratory and clinical data available to the clinician.
Department (code)	Molecular
Methodology	Aptima nucleic acid amplification
Estimated TAT	1–3 business days from receipt
Testing Schedule	Monday–Friday
Retention	Specimen is retained for 21 days from submission
CPT Code(s)	87624
Collection File	View/Download File